# HTR3B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *HTR3B* gene encodes a subunit of the 5-HT3 receptor, a ligand-gated cation channel crucial for fast excitatory serotonergic neurotransmission in the central and peripheral nervous systems. This receptor is a primary target for antiemetic drugs like ondansetron and granisetron.
- Genetic variations in *HTR3B*, such as the rs1176744 (p.Tyr129Ser) polymorphism, are robustly associated with susceptibility to postoperative and chemotherapy-induced nausea/vomiting, as well as influencing pain perception and response to 5-HT3 antagonists.
- The 5-HT3B subunit significantly alters the biophysical properties of the heteromeric 5-HT3 receptor compared to homomeric 5-HT3A receptors, including reduced ion conductance and calcium permeability, which impacts cellular signaling and drug efficacy.
- *HTR3B* genetic variants are implicated in a range of neuropsychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and various substance use disorders (alcohol, heroin, nicotine, cocaine), suggesting a role in modulating mood, cognition, and addiction pathways.
- The *HTR3B* gene exhibits tissue-specific promoter usage in the brain and intestine, allowing for differential regulation of receptor expression and contributing to distinct physiological roles and potential therapeutic targeting strategies in different organ systems.
- Pharmacogenetic studies highlight that *HTR3B* genotype can predict individual response to 5-HT3 receptor antagonists, informing personalized antiemetic regimens and potential treatments for alcohol use disorder and irritable bowel syndrome.

---

## Executive Summary & Key Metadata

The *HTR3B* gene encodes the 5-hydroxytryptamine (serotonin) receptor 3B subunit, an integral membrane protein that assembles with other 5-HT3 subunits to form the pentameric 5-HT3 receptor, a ligand-gated cation channel. This receptor mediates fast excitatory serotonergic neurotransmission in the central and peripheral nervous systems and is a principal molecular target for antiemetic drugs (e.g., ondansetron, granisetron) and several neuropsychiatric medications. The 5-HT3B subunit confers distinct biophysical properties to the heteromeric receptor, including altered ion conductance, calcium permeability, and desensitization kinetics, compared with homomeric 5-HT3A receptors. Genetic variation in *HTR3B* has been robustly associated with susceptibility to postoperative and chemotherapy-induced nausea/vomiting, psychiatric disorders (depression, schizophrenia, bipolar disorder, alcohol and substance use disorders), irritable bowel syndrome, and pharmacotherapeutic outcomes.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | HTR3B |
| **UniProt Accession** | O95264 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 11q23.2 (GRCh38: chr11:113,798,695–113,837,260; minus strand) |
| **Primary Molecular Function** | Serotonin-gated ion channel subunit; forms heteropentameric 5-HT3AB receptors with 5-HT3A; mediates fast depolarizing Na⁺/K⁺/Ca²⁺ currents |
| **Disease & Pathology Associations** | Postoperative nausea/vomiting (PONV), chemotherapy-induced nausea/vomiting (CINV), major depressive disorder (MDD), schizophrenia (treatment-resistant), bipolar disorder, alcohol use disorder (AUD), substance dependence (heroin, cocaine, nicotine), irritable bowel syndrome (IBS), eating disorders, fibromyalgia, antipsychotic-induced weight gain and hyperprolactinemia, type 2 diabetes (T2D), osteoarthritis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

*HTR3B* is located on the long arm of chromosome 11 at cytogenetic band 11q23.2. The gene spans approximately 38.6 kilobases (kb) of genomic DNA on the minus (reverse) strand. The reference genome assembly (GRCh38/hg38) places the gene between coordinates 113,798,695 and 113,837,260. The gene comprises nine exons and eight introns, with the translation start codon (ATG) located in exon 1 and the stop codon in exon 9. The coding sequence (CDS) is 1,326 nucleotides in length, encoding a protein of 441 amino acids (UniProt O95264).

The genomic organization of *HTR3B* is notable for its proximity to other 5-HT3 receptor subunit genes. The 5-HT3 receptor subunit gene cluster on chromosome 11q23 includes *HTR3A*, *HTR3B*, *HTR3C*, *HTR3D*, and *HTR3E* in a tandem array. *HTR3B* is positioned between *HTR3A* (centromeric) and *HTR3C* (telomeric). This clustering suggests shared regulatory elements and coordinated transcriptional control, although each gene possesses its own promoter architecture.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *HTR3B* lacks a canonical TATA box but contains multiple GC-rich regions and putative binding sites for ubiquitous and tissue-specific transcription factors. *In silico* promoter analysis has identified consensus sequences for Sp1 (specificity protein 1), AP-2 (activator protein 2), and members of the ETS family of transcription factors. These elements are consistent with the broad but tissue-restricted expression pattern of *HTR3B*, which is most abundant in the brain (hippocampus, amygdala, cortex), dorsal root ganglia, and the enteric nervous system.

A critical regulatory feature is the presence of alternative promoters that drive tissue-specific expression. Tzvetkov et al. (2007) demonstrated that *HTR3B* utilizes distinct alternative promoters in the human brain and intestine. In the brain, transcription initiates from a proximal promoter region approximately 1.5 kb upstream of the translation start site. In the intestine, an alternative distal promoter located further upstream (approximately 4.5 kb from the ATG) drives expression. These alternative promoters produce transcripts with different 5' untranslated regions (UTRs) but identical coding sequences, suggesting that the resulting proteins are identical. The existence of tissue-specific promoters provides a mechanism for differential regulation of *HTR3B* expression in the central nervous system versus the periphery, which has implications for tissue-specific drug targeting and side effect profiles.

### 1.3 Transcription Factor Binding and Epigenetic Regulation

Chromatin immunoprecipitation (ChIP) data from ENCODE and related projects indicate that the *HTR3B* promoter and enhancer regions are enriched for histone H3 lysine 4 trimethylation (H3K4me3), a mark associated with active transcription. DNA methylation analysis has revealed CpG islands in the promoter region, and methylation status at specific CpG sites has been correlated with *HTR3B* expression levels in brain tissue. A study by Han et al. (2018) performed cis-methylation quantitative trait locus (cis-mQTL) analysis and identified that SNPs in *HTR3B* are associated with differential DNA methylation at nearby CpG sites, suggesting that genetic variation can influence gene expression through epigenetic mechanisms.

### 1.4 Alternative Splicing and Isoforms

While the canonical *HTR3B* transcript encodes the full-length 441-amino acid protein, alternative splicing events have been documented. The most well-characterized splice variant results from exon 6 skipping, which produces a truncated protein lacking a portion of the large intracellular loop between transmembrane domains 2 and 3 (TM2-TM3). This variant, if translated, would lack critical residues involved in channel gating and intracellular trafficking. However, the functional significance of this isoform *in vivo* remains uncertain, as it may be subject to nonsense-mediated mRNA decay.

The HTR3B allelic variant database curated by Celli et al. (2017) catalogues numerous splice-site variants and their potential effects on transcript processing. Notably, the intronic variant rs3782025 (IVS5+37A>G) has been investigated for its association with altered splicing efficiency, although functional studies have not demonstrated a consistent effect on exon inclusion rates.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Topology and Domain Organization

The 5-HT3B subunit (441 amino acids, ~50 kDa) belongs to the Cys-loop superfamily of pentameric ligand-gated ion channels (pLGICs), which also includes nicotinic acetylcholine receptors (nAChRs), GABA-A receptors, and glycine receptors. The protein adopts a characteristic topology with four transmembrane domains (TM1–TM4), a large extracellular N-terminal domain, and a short extracellular C-terminus.

**Domain boundaries (based on UniProt O95264 and homology models):**

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal peptide | 1–22 | Directs co-translational insertion into the ER membrane; cleaved in mature protein |
| Extracellular N-terminal domain | 23–245 | Contains the orthosteric serotonin binding site; forms the "Cys-loop" (Cys-160 to Cys-175); mediates subunit assembly interfaces |
| Transmembrane domain 1 (TM1) | 246–270 | Lines the ion channel pore; contributes to the hydrophobic gate |
| Intracellular loop (TM1-TM2) | 271–290 | Contains the amphipathic helix (MA helix); interacts with intracellular scaffolding proteins |
| Transmembrane domain 2 (TM2) | 291–315 | Primary pore-lining helix; determines ion selectivity and conductance |
| Intracellular loop (TM2-TM3) | 316–360 | Critical for coupling agonist binding to channel opening; contains phosphorylation sites |
| Transmembrane domain 3 (TM3) | 361–385 | Structural support; interacts with TM1 and TM2 |
| Intracellular loop (TM3-TM4) | 386–420 | Large cytoplasmic loop; contains trafficking motifs and protein interaction sites |
| Transmembrane domain 4 (TM4) | 421–441 | Lipid-facing helix; anchors the receptor in the membrane |

### 2.2 The Extracellular Domain and Ligand Binding

The N-terminal extracellular domain adopts a β-sandwich fold composed of ten β-strands arranged in two sheets. The orthosteric serotonin binding site is located at the interface between two adjacent subunits, a feature common to all Cys-loop receptors. In the heteromeric 5-HT3AB receptor, the principal (+) face of the binding site is contributed by the 5-HT3A subunit, while the complementary (−) face is contributed by the 5-HT3B subunit. This arrangement means that the 5-HT3B subunit contributes residues to the binding pocket, and variations in these residues can alter agonist affinity and efficacy.

The signature Cys-loop motif (Cys-160 and Cys-175 in HTR3B) forms a disulfide bond that stabilizes the extracellular domain. This structural feature is essential for proper protein folding and receptor assembly. Mutations that disrupt the Cys-loop disulfide bond result in ER retention and proteasomal degradation of the subunit.

### 2.3 Transmembrane Domain and Ion Pore

The TM2 domain of each subunit lines the central ion-conducting pore. In the pentameric receptor, five TM2 helices (one from each subunit) form a funnel-shaped channel. The 5-HT3B subunit's TM2 domain contains residues that differ markedly from the 5-HT3A subunit, and these differences account for the distinct biophysical properties of heteromeric versus homomeric receptors.

Key residues in TM2 of 5-HT3B include:

- **Glu-297** (equivalent to Ala-251 in 5-HT3A): The presence of a negatively charged glutamate at this position in 5-HT3B dramatically reduces calcium permeability and single-channel conductance. Homomeric 5-HT3A receptors have a large conductance (~0.4–0.8 pS) and significant Ca²⁺ permeability (PCa/PNa ≈ 1.1), whereas heteromeric 5-HT3AB receptors have a much smaller conductance (~0.1 pS) and reduced Ca²⁺ permeability (PCa/PNa ≈ 0.3).
- **Arg-304** (equivalent to Thr-264 in 5-HT3A): This positively charged residue in the intracellular end of TM2 contributes to the selectivity filter and affects the rectification properties of the channel.

### 2.4 Structural Models and PDB Availability

To date, no high-resolution crystal structure of the 5-HT3B subunit alone has been determined. However, cryo-electron microscopy (cryo-EM) structures of the heteromeric 5-HT3AB receptor have been solved, most notably the mouse 5-HT3A homomer (PDB: 6Y1Z, 6Y2A) and the human 5-HT3A/B heteromer (PDB: 6Y1Y, 6Y20). These structures provide atomic-level detail of the pentameric assembly, including the subunit stoichiometry (2A:3B or 3A:2B, depending on expression conditions) and the conformational changes associated with channel gating.

Homology models of the human 5-HT3B subunit can be generated using these cryo-EM structures as templates, with sequence identity between human 5-HT3A and 5-HT3B of approximately 44%. The models reveal that the 5-HT3B subunit maintains the overall Cys-loop fold but exhibits distinct electrostatic surface properties, particularly in the extracellular vestibule and the intracellular portal regions.

> **Interactive 3D Protein Visualizer: Load HTR3B (PDB: true)**
> [Interactive 3D Protein Visualizer: Load HTR3B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95264)
> *Explore the 3D architecture of the 5-HT3B subunit, including the extracellular ligand-binding domain, the four transmembrane helices, and the intracellular loops. The visualizer allows you to highlight specific residues implicated in disease-associated variants (e.g., Tyr-129, Ala-223, Val-344) and to examine the electrostatic surface potential.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The 5-HT3 Receptor: A Ligand-Gated Ion Channel

The 5-HT3 receptor is the only serotonin receptor subtype that functions as a ligand-gated ion channel; all other 5-HT receptors (5-HT1, 5-HT2, 5-HT4, 5-HT5, 5-HT6, 5-HT7) are G protein-coupled receptors (GPCRs). The 5-HT3 receptor is a pentameric cation-selective channel that, upon binding serotonin, undergoes a conformational change from a closed to an open state, allowing the influx of Na⁺ and Ca²⁺ and the efflux of K⁺. The resulting depolarization triggers fast excitatory postsynaptic potentials (EPSPs) in neurons.

### 3.2 Subunit Composition and Stoichiometry

The 5-HT3 receptor can assemble as a homomer of five 5-HT3A subunits or as heteromers containing 5-HT3A plus one or more of the other subunits (5-HT3B, 5-HT3C, 5-HT3D, 5-HT3E). The 5-HT3B subunit cannot form functional homomeric receptors; it must co-assemble with 5-HT3A. The stoichiometry of the heteromeric 5-HT3AB receptor has been debated, with evidence supporting both 2A:3B and 3A:2B arrangements. Cryo-EM studies of the human receptor suggest a preferred stoichiometry of 2A:3B, with the two 5-HT3A subunits positioned non-adjacently.

The incorporation of the 5-HT3B subunit into the receptor complex has profound functional consequences:

1. **Reduced single-channel conductance**: The 5-HT3AB receptor has a conductance of ~0.1 pS, compared with ~0.4–0.8 pS for the 5-HT3A homomer.
2. **Reduced Ca²⁺ permeability**: The Ca²⁺/Na⁺ permeability ratio decreases from ~1.1 (homomeric) to ~0.3 (heteromeric).
3. **Altered desensitization kinetics**: Heteromeric receptors desensitize more slowly and recover from desensitization more rapidly than homomeric receptors.
4. **Altered pharmacology**: The 5-HT3B subunit influences the potency of competitive antagonists, with some antagonists (e.g., ondansetron) showing reduced potency at heteromeric receptors.

### 3.3 Signal Transduction and Downstream Effectors

Although the primary action of the 5-HT3 receptor is to mediate fast ionotropic signaling, receptor activation also triggers downstream intracellular signaling cascades. The Ca²⁺ influx through the receptor can activate:

- **Calmodulin (CaM)-dependent pathways**: Ca²⁺ binding to calmodulin activates CaM kinase II (CaMKII), which phosphorylates various substrates, including the transcription factor CREB (cAMP response element-binding protein), leading to changes in gene expression.
- **Nitric oxide (NO) signaling**: Ca²⁺-dependent activation of neuronal nitric oxide synthase (nNOS) produces NO, which acts as a retrograde messenger and modulates synaptic plasticity.
- **MAPK/ERK pathway**: In some cell types, 5-HT3 receptor activation has been shown to stimulate the extracellular signal-regulated kinase (ERK) pathway, promoting cell survival and differentiation.

In the enteric nervous system, 5-HT3 receptors on vagal afferent terminals and myenteric neurons modulate gastrointestinal motility, secretion, and visceral sensation. Activation of 5-HT3 receptors on enterochromaffin cells and intrinsic primary afferent neurons triggers the peristaltic reflex and transmits nausea and emesis signals to the brainstem.

### 3.4 Protein-Protein Interaction Network

The intracellular loops of the 5-HT3B subunit contain multiple motifs for protein-protein interactions. Key interacting partners identified through yeast two-hybrid screens and co-immunoprecipitation studies include:

- **RACK1 (Receptor for Activated C Kinase 1)**: Binds to the large intracellular loop (TM3-TM4) of 5-HT3 subunits and anchors protein kinase C (PKC) to the receptor, facilitating phosphorylation-dependent modulation.
- **GABA-A receptor-associated protein (GABARAP)**: Interacts with the TM3-TM4 loop and promotes receptor trafficking to the cell surface.
- **AP-2 (Adaptor Protein complex 2)**: Mediates clathrin-dependent endocytosis of the receptor, regulating cell surface expression.
- **14-3-3 proteins**: Bind to phosphorylated serine/threonine residues in the intracellular loop and modulate receptor desensitization.

STRING interaction network analysis predicts that HTR3B has functional associations with HTR3A, HTR3C, HTR3D, HTR3E, and SLC6A4 (serotonin transporter), reflecting the coordinated regulation of serotonergic signaling.

### 3.5 Regulatory Feedback Loops

The 5-HT3 receptor is subject to multiple layers of regulation:

1. **Phosphorylation**: PKC phosphorylation of serine residues in the TM3-TM4 loop (e.g., Ser-409, Ser-418 in 5-HT3B) enhances receptor desensitization. PKA phosphorylation has also been reported to modulate receptor function.
2. **Transcriptional regulation**: Chronic exposure to serotonin or 5-HT3 receptor agonists leads to receptor downregulation, while antagonist exposure can cause upregulation (receptor sensitization).
3. **miRNA-mediated regulation**: Several microRNAs (e.g., miR-15a, miR-16) have been predicted to target the 3' UTR of HTR3B mRNA, providing a post-transcriptional mechanism for regulating receptor expression.

```mermaid
sequenceDiagram
    participant 5HT as "Serotonin (5-HT)"
    participant R as "5-HT3AB Receptor"
    participant P as "Ion Pore (Na+/Ca2+)"
    participant C as "CaM/CaMKII"
    participant T as "Transcription Factors (CREB)"
    participant G as "Gene Expression"
    5HT->>R: Binds orthosteric site
    R->>P: Conformational change (open state)
    P->>C: Ca2+ influx
    C->>T: Phosphorylation cascade
    T->>G: Modulate target gene transcription
    G-->>R: Feedback (receptor expression changes)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Common Polymorphisms and Functional Variants

The *HTR3B* gene is highly polymorphic, with numerous single nucleotide polymorphisms (SNPs) identified in coding and non-coding regions. The most extensively studied functional variants are:

**rs1176744 (p.Tyr129Ser; Y129S)**: This missense variant in exon 5 results in a tyrosine-to-serine substitution at position 129 in the extracellular domain. The variant is located near the Cys-loop and is predicted to affect receptor assembly and trafficking. Functional studies by Walstab et al. (2008) demonstrated that the 129Ser allele significantly reduces cell surface expression of the 5-HT3AB receptor and alters the receptor's biophysical properties. This variant has been associated with:

- **Postoperative nausea and vomiting (PONV)**: Multiple studies in Chinese Han populations have found that the rs1176744 A allele (encoding Ser-129) is associated with increased risk of PONV.
- **Irritable bowel syndrome (IBS)**: Berens et al. (2022) reported an association between rs1176744 and psychosomatic symptoms in IBS patients.
- **Pain catastrophizing**: Horjales-Araujo et al. (2013) found that the rs1176744 variant is associated with pain catastrophizing, a psychological factor that predicts pain perception.
- **Experimental pain sensitivity**: Louca Jounger et al. (2016) demonstrated that rs1176744 influences pain perception and the analgesic efficacy of the 5-HT3 antagonist granisetron.

**rs2276307 (p.Ala223Thr; A223T)**: This variant in exon 7 results in an alanine-to-threonine substitution in the extracellular domain near the TM1 boundary. The 223Thr allele has been associated with altered receptor function and increased risk of depression in some populations.

**rs3782025 (IVS5+37A>G)**: This intronic variant has been associated with schizophrenia, particularly treatment-resistant schizophrenia (TRS), in a Japanese population. The mechanism is unclear but may involve altered splicing or linkage disequilibrium with functional coding variants.

**rs1672717 (c.*+151A>G)**: Located in the 3' UTR, this variant has been associated with bipolar disorder in a European multicenter study and with vomiting after breast surgery in Chinese Han females.

**Promoter deletion-insertion polymorphism (-100_-102delAAG)**: Meineke et al. (2008) characterized a 3-bp deletion in the promoter region that affects transcription factor binding and reduces promoter activity. This polymorphism has been associated with altered HTR3B expression and may contribute to interindividual differences in receptor density.

### 4.2 Rare Variants and Mutational Spectrum

The HTR3B allelic variant database catalogues over 100 rare variants, including missense, nonsense, frameshift, and splice-site mutations. Notable rare variants include:

- **p.Trp36Ter (W36X)**: A nonsense mutation in exon 1 that introduces a premature stop codon, resulting in a severely truncated protein lacking all transmembrane domains. This variant is predicted to be null and would result in haploinsufficiency.
- **p.Arg344His (R344H)**: A missense variant in the TM2-TM3 intracellular loop, a region critical for channel gating. Functional studies suggest this variant alters the coupling between agonist binding and channel opening.
- **p.Gly405Asp (G405D)**: A missense variant in the large intracellular loop (TM3-TM4) that may disrupt interactions with intracellular scaffolding proteins such as RACK1.

### 4.3 Disease Associations

#### 4.3.1 Psychiatric Disorders

**Major Depressive Disorder (MDD)**: Yamada et al. (2006) identified an association between HTR3B haplotypes and female major depression in a Japanese population. Wang et al. (2023) confirmed that HTR3B polymorphisms are associated with depression and executive dysfunction in a Chinese Han population. The rs1176744 variant has been implicated in antidepressant treatment response, with some studies showing that carriers of the 129Ser allele have poorer response to selective serotonin reuptake inhibitors (SSRIs).

**Bipolar Disorder**: Frank et al. (2004) investigated HTR3B in bipolar affective disorder and schizophrenia but found no significant association. However, a later European multicenter study by Hammer et al. (2012) replicated an association between functional HTR3A and HTR3B variants and bipolar disorder. Jian et al. (2016) also reported associations of HTR3A, HTR3B, and HTR3A haplotypes with bipolar disorder in Chinese patients.

**Schizophrenia**: Ji et al. (2008) found an association between HTR3B and treatment-resistant schizophrenia in a Japanese population. Schuhmacher et al. (2009) investigated the influence of 5-HT3 receptor subunit genes on antipsychotic treatment response but found no significant association with HTR3B. Gutiérrez et al. (2002) reported that novel mutations in HTR3A and HTR3B are not associated with clozapine response.

**Obsessive-Compulsive Disorder (OCD)**: Kim et al. (2016) found that common variants of HTR3 genes, including HTR3B, are associated with OCD and its phenotypic expression.

#### 4.3.2 Substance Use Disorders

**Alcohol Use Disorder (AUD)**: Ducci et al. (2009) reported that HTR3B is associated with alcoholism with antisocial behavior and alpha EEG power. Enoch et al. (2010) found that functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence. Seneviratne et al. (2013) demonstrated association, interaction, and replication of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence. Li et al. (2025) investigated the association between 5-HTRs gene polymorphism and AUD in Han males from Yunnan, China.

**Heroin Dependence**: Yin et al. (2016) found that polymorphisms in HTR3B are associated with heroin dependence in the Chinese Han population. Levran et al. (2008) identified HTR3B as a susceptibility gene for heroin addiction.

**Nicotine Dependence**: Yang et al. (2013) demonstrated that serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions. Han et al. (2018) performed association and cis-mQTL analysis of variants in serotonergic genes associated with nicotine dependence in Chinese Han smokers.

**Cocaine Dependence**: Yang and Li (2014) analyzed association and interaction of 5-HT3 receptor and serotonin transporter genes with alcohol, cocaine, and nicotine dependence using the SAGE data.

#### 4.3.3 Nausea and Vomiting

**Postoperative Nausea and Vomiting (PONV)**: Rueffert et al. (2009) investigated whether variations in HTR3A and HTR3B influence the occurrence of postoperative vomiting. Ma et al. (2013) found that polymorphisms of HTR3B are associated with post-surgery emesis in a Chinese Han population. Yan et al. (2021) studied polymorphisms of HTR3B and clinical characteristics for vomiting after breast surgery in Chinese Han females. Susan et al. (2026) examined the association of PONV and genotypes of 5-HT3RB in Indian women undergoing surgery.

**Chemotherapy-Induced Nausea and Vomiting (CINV)**: Yeo et al. (2025) conducted a pharmacogenetic analysis of HTR3A, HTR3B, and TACR1 for personalized prophylactic antiemetic regimens for CINV. Jin et al. (2023) investigated the association between gene polymorphisms and cisplatin chemotherapy-induced nausea and vomiting. Eliasen et al. (2021) studied background sensitivity to CINV and response to antiemetics in pediatric patients.

**Nausea and Vomiting of Pregnancy (NVP)**: Lehmann et al. (2013) evaluated pharmacogenetic predictors of NVP severity and response to antiemetic therapy.

#### 4.3.4 Irritable Bowel Syndrome (IBS)

Berens et al. (2022) conducted a multicenter retrospective study on serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in IBS. The study found that HTR3B variants, particularly rs1176744, are associated with IBS symptom severity and psychological comorbidity. Gunn et al. (2019) discussed understanding differences in patient response to ondansetron in IBS with diarrhea.

#### 4.3.5 Other Conditions

**Eating Disorders**: Hammer et al. (2009) found that functional variants of the serotonin receptor type 3A and B genes are associated with eating disorders.

**Fibromyalgia**: Frank et al. (2004) performed mutational analysis of HTR3A and HTR3B in fibromyalgia patients. Janssen et al. (2021) reviewed related polymorphisms and clinical relevance in fibromyalgia.

**Antipsychotic-Induced Weight Gain (AIWG)**: Zai et al. (2017) conducted an association study of serotonin 3 receptor subunit gene variants in antipsychotic-induced weight gain.

**Antipsychotic-Induced Hyperprolactinemia**: Ivanova et al. (2017) identified 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. Osmanova et al. (2016) studied gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients.

**Tardive Dyskinesia**: Pozhidaev et al. (2020) investigated 5-hydroxytryptamine receptors and tardive dyskinesia in schizophrenia.

**Type 2 Diabetes (T2D)**: Kwon et al. (2019) found that serotonin receptor 3B polymorphisms are associated with type 2 diabetes in the Korean Genome and Epidemiology Study.

**Osteoarthritis**: Liu et al. (2024) identified ion channel-related genes, including HTR3B, as diagnostic markers and potential therapeutic targets for osteoarthritis.

**Statin-Related Myalgia**: Ruaño et al. (2007) conducted a physiogenomic association study of statin-related myalgia to serotonin receptors.

**Paroxetine-Induced Nausea**: Sugai et al. (2006) studied the effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine.

**Methotrexate-Induced Nausea**: Kyvsgaard et al. (2020) investigated single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

The direct interaction of the 5-HT3B receptor with viral or bacterial pathogens is not well established. However, several indirect connections merit discussion:

### 5.1 Gut Microbiota and Serotonergic Signaling

The gut microbiota profoundly influences host serotonin signaling, and HTR3B expression in the enteric nervous system is modulated by microbial composition. Pan et al. (2019) demonstrated that absence of gut microbiota during early life affects anxiolytic behaviors and monoamine neurotransmitter systems in the hippocampus of mice, with alterations in serotonin-related gene expression. Yaghoubfar et al. (2023) investigated the impact of *Akkermansia muciniphila* and its extracellular vesicles on the regulation of serotonergic gene expression in the small intestine of mice, finding that this commensal bacterium modulates HTR3B expression.

### 5.2 Viral Infections and Serotonergic Dysregulation

While no specific viral oncoprotein has been shown to directly target HTR3B, viral infections that cause systemic inflammation can dysregulate serotonergic signaling. For example, SARS-CoV-2 infection has been associated with alterations in serotonin metabolism, and the resulting "serotonin storm" may impact 5-HT3 receptor function. However, direct evidence for viral modulation of HTR3B expression or function is lacking.

### 5.3 Cancer and HTR3B Expression

Chakrabarti et al. (2015) performed whole-genome expression profiling in chewing-tobacco-associated oral cancers and identified alterations in serotonin receptor gene expression, including HTR3B. The role of 5-HT3 receptors in cancer biology is an emerging area of research, with evidence suggesting that serotonin can act as a growth factor for certain tumors. However, the specific contribution of HTR3B to tumorigenesis remains to be fully elucidated.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 5-HT3 Receptor Antagonists (Setrons)

The 5-HT3 receptor is a well-validated therapeutic target, and 5-HT3 receptor antagonists (commonly known as "setrons") are widely used clinically. These drugs are competitive antagonists that bind to the orthosteric serotonin binding site and prevent channel opening.

**FDA-Approved 5-HT3 Antagonists:**

| **Drug** | **Indications** | **Notes** |
|---|---|---|
| **Ondansetron (Zofran)** | CINV, PONV, radiation-induced nausea/vomiting, hyperemesis gravidarum (off-label) | Most widely studied; genetic variation in HTR3B influences response |
| **Granisetron (Kytril)** | CINV, PONV | Higher affinity for 5-HT3 receptors than ondansetron; used in experimental pain studies |
| **Dolasetron (Anzemet)** | CINV, PONV | Prodrug; active metabolite hydrodolasetron |
| **Palonosetron (Aloxi)** | CINV (acute and delayed) | Second-generation; allosteric binding and prolonged receptor inhibition |
| **Ramosetron (Nasea)** | CINV, IBS-D (in Japan) | High potency; used for diarrhea-predominant IBS |
| **Tropisetron (Navoban)** | CINV | Also has α7 nicotinic receptor agonist activity |

### 6.2 Pharmacogenetic-Guided Therapy

The clinical response to 5-HT3 antagonists varies considerably among individuals, and genetic variation in HTR3B contributes to this variability.

**Ondansetron and Alcohol Use Disorder**: Johnson et al. (2013) determined genotype combinations that can predict the outcome of treatment of alcohol dependence using ondansetron. The study found that individuals with specific HTR3A and HTR3B genotypes (including rs1176744) showed significantly greater reduction in drinking intensity with ondansetron treatment. Seneviratne et al. (2022) conducted a randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating AUD, confirming that genetic variation in HTR3B predicts treatment response.

**Ondansetron and PONV**: Shinn et al. (2011) investigated genetic polymorphisms in HTR3B and the clinical response to ondansetron in Koreans. The study found that the rs1176744 variant was associated with reduced antiemetic efficacy of ondansetron.

**Personalized Antiemetic Regimens for CINV**: Yeo et al. (2025) conducted a pharmacogenetic analysis of HTR3A, HTR3B, and TACR1 to develop personalized prophylactic antiemetic regimens for CINV. The study demonstrated that genotype-guided selection of antiemetic therapy significantly improved nausea and vomiting control compared with standard therapy.

### 6.3 Investigational Drugs and Future Directions

**5-HT3 Antagonists in IBS**: Ramosetron and ondansetron are being investigated for the treatment of diarrhea-predominant IBS (IBS-D). Gunn et al. (2019) discussed the role of HTR3B genotypes in predicting response to ondansetron in IBS-D.

**5-HT3 Antagonists in Pain**: Louca Jounger et al. (2016) investigated the influence of HTR3A and HTR3B polymorphisms on experimental pain and the effect of granisetron. The results suggest that 5-HT3 antagonists may have analgesic properties in specific genetic subgroups.

**5-HT3 Antagonists in Psychiatric Disorders**: The potential use of 5-HT3 antagonists as adjunctive treatment for schizophrenia, anxiety, and substance use disorders is under investigation. The pharmacogenetic data from HTR3B studies may inform patient selection for these trials.

### 6.4 Gene Therapy and RNA-Based Approaches

While no gene therapy targeting HTR3B is currently in clinical development, the gene's role in neuropsychiatric disorders makes it a potential target for future RNA-based therapeutics. Antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) could theoretically be used to downregulate HTR3B expression in specific brain regions, although the challenges of CNS delivery remain substantial.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 51081 | https://www.ncbi.nlm.nih.gov/gene/51081 |
| **Ensembl** | ENSG00000149305 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149305 |
|

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)